Literature Review

Trends in preferred place of death among patients with bladder cancer in the United States, 2000 to 2020Palliative & Supportive Care; by Manas Pustake, Atharva Railkar, Mohammad Arfat Ganiyani, Atulya Aman Khosla, Avi Harisingani, Hanzala Jehangir, Mostafa Eysha, Divya Samat, Taha Hassan, Rohan Garje; 4/26Understanding trends in end-of-life care for bladder cancer patients is essential in improving palliative care planning. This study analyzes trends in preferred place of death among bladder cancer patients in the United States from year 2000 to 2020. Black individuals had significantly lower odds of hospice use than White patients ... and hospice use increased annually by an average of 13.4% ...  Interestingly, younger individuals were more likely to die in hospice compared to those aged 85 years or older, though the odds decreased with age. The results indicate that utilization of hospice care and home-based end-of-life care have risen in prominence though disparities are present across racial and regional groups.

Communication processes and priorities in Medical Aid in Dying conversations: A cross-sectional qualitative study of multidisciplinary cancer cliniciansCancer Medicine; by Meghan McDarby, Alix Youngblood, Megan Miller, William E Rosa, Haley Buller, Betty R Ferrell; 4/26Medical aid in dying (MAiD) is a practice that enables eligible individuals with a terminal, life-limiting illness to end their lives in a self-directed way. Multidisciplinary care teams play a vital role in facilitating discussions and patient decision making about MAiD in cancer care settings. Four themes were identified as communication priorities and processes critical for multidisciplinary teams when discussing MAiD with cancer patients: (1) addressing complexity of MAiD ... ; (2) thorough palliative care assessment; (3) strategies for clinicians and healthcare systems to optimize MAiD discussions; and (4) person-centered care that de-stigmatizes MAiD. Findings underscore the distinct complexity of MAiD discussions in oncology and highlight the need for tailored, person-centered approaches that go beyond standard end-of-life communication.

U.S. hospice market size to reach $45.3 billion by 2033 Grand View Research; April 2026 The U.S. hospice market size is estimated to reach USD 45.3 billion by 2033, registering a CAGR of 4.8% from 2026 to 2033, according to a new report by Grand View Research, Inc. 

Hope, uncertainty, and hard truths: the complexity of goals-of-care discussions in oncology OncLive - Oncology Live; by Maurie Markman, MD; 4/10/26 ... While appreciating considerable variation in how individuals deal with their [cancer] diagnosis, as well as understanding the potential for difficult conversations regarding the specifics of available therapeutic options and anticipated statistically defined survival, it remains essential that such discussions be held. ... What is the most appropriate conclusion regarding a goals-of-care discussion? Should this patient have been offered further testing and therapy, or, based on the facts of this case, was hospice referral perhaps a more reasonable suggestion?

Second-generation antipsychotics for depression in serious illness: A first-line augmentation strategyJournal of Pain & Symptom Management; by Gregg Robbins-Welty, Mia Pattillo, Danielle Chammas, Karolina Sadowska, Cara L McDermott, Nneka Ufere, Jason A Webb, Daniel Shalev; 3/26Depression in serious illness is common, disabling, and often requires rapid improvement. In the psychiatric literature, SGA [second-generation antipsychotics] augmentation improves response and remission rates ... , with onset of improvement within 1-2 weeks. Monotherapy is less well tolerated and not guideline-recommended. No RCTs have evaluated SGAs specifically for depression in serious illness, but numerous cancer trials support their safety for nausea, appetite, and other symptoms. Despite the absence of serious illness-specific psychiatric trials, SGAs have the strongest evidence base among augmentation options and may offer meaningful benefits when prognosis or symptom severity necessitates rapid improvement. Low-dose augmentation should be considered early, rather than only after multiple failed antidepressants, particularly when SGAs can also target co-occurring physical symptoms relevant to palliative care.

Kelly, DelBene introduce Concurrent Care for Comfort Act U.S. Representative Mike Kelly, Washington, DC; Press Release; 4/20/26 Today, U.S. Representatives Mike Kelly (R-PA), a member of the Ways & Means Subcommittee on Health, and Suzan DelBene (D-WA) introduced the Concurrent Care for Comfort Act, legislation that seeks to improve patient care and outcomes for Americans on Medicare who receive dialysis treatment. Currently, Americans living with end stage renal disease (ESRD) are not permitted to continue their dialysis treatment under Medicare to enter palliative hospice care. This legislation would amend Medicare policy to allow for Americans to continue their treatment, enter hospice, and be with their family pain-free.

Sovereign Hospice: addressing late-stage renal condition care gaps in Fort Worth MyCarrollCountyNews.com, Dallas, TX; by Sovereign Hospice; 4/16/26 End-stage kidney disease affects hundreds of thousands of Americans each year. When kidneys can no longer sustain life without dialysis or a transplant, families are left to make decisions that few feel prepared for. Sovereign Hospice ... is drawing attention to a gap many families face: not knowing that hospice care services exist as a legitimate, fully supported option at this stage of illness. ... For patients with end-stage kidney disease, the shift away from aggressive treatment means that symptom management becomes the priority. Common symptoms at this stage include fatigue, pain, restlessness, and fluid retention. The interdisciplinary team is trained to address all of these through individualized care plans.

Racial disparities in non-stigmatized supportive care medication use in pancreatic cancerJournal of Pain & Symptom Management; by Olga Monika Trejos Kweyete, Chardaé Whitner, David L. Deremer, Yi Guo, Jiang Bian, Lisa Scarton, Sherise C. Rogers, Diana J. Wilkie, Xiwei Lou, John M. Allen; 3/26Pancreatic cancer (PC) is associated with a high symptom burden that contributes to reduced health-related quality of life (HRQoL) and adverse clinical outcomes. This study examined racial and ethnic differences in the use of non-stigmatized SCMs [supportive care medications] during end-of-life care among patients with PC. SCM use was defined as at least one outpatient prescription claim for antiemetics, appetite stimulants, cognitive aids, headache aids, or sleep aids. Racial and ethnic disparities persist in the use of non-stigmatized SCMs among patients with PC at the end of life. These findings extend prior evidence on inequities in cancer symptom management and underscore the need for interventions that promote equitable access to supportive care medications across diverse populations.